Here, we performed a retrospective study to determine whether CTRB2ex6 deletions are associated with response to chemotherapy, time to cancer progression, or overall survival (OS) in PDAC patients.<h4>Methods</h4>The study included CTRB2 genotype data from two independent PDAC cohorts (Cohort 1: n = 633; Cohort 2: n = 3,896). Here, CTRB2 is linked to cancer.